Bristol-Myers Squibb Ranks 82nd in Trading Volume as Stock Drops 2.61% Amid Clinical Trial and Expansion Plans

On April 15, 2025, Bristol-Myers Squibb (BMY) closed with a trading volume of 7.60 billion, ranking 82nd in the day's stock market activity, and the stock price fell by 2.61%.

Bristol-Myers Squibb has announced that it will be conducting a clinical trial for its new drug, which is designed to treat a rare form of cancer. The trial will involve 500 patients and is expected to last for two years. The company hopes that the results of the trial will provide valuable insights into the drug's efficacy and safety.

Bristol-Myers Squibb has also announced that it will be expanding its manufacturing capabilities in order to meet the growing demand for its products. The company plans to invest $500 million in a new manufacturing facility, which will be located in the United States. The facility is expected to create 1,000 new jobs and will be operational by the end of 2026.

Bristol-Myers Squibb has also announced that it will be acquiring a smaller biotech company in order to expand its portfolio of cancer treatments. The acquisition is expected to be completed by the end of the year, and the terms of the deal have not been disclosed. The acquisition is expected to strengthen Bristol-Myers Squibb's position in the cancer treatment market.